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Abstract
There have been unprecedented advances in the management of B-cell lymphoma in the last decade.
These include staging, treatment, and bench observations.
Introduction and context
Significant changes in the staging, outcome, and
management of B-cell lymphomas have occurred over
the last decade. Monoclonal antibodies, unconjugated or
conjugated to radioisotopes, that target lymphoma-
specific surface markers have changed the natural history
of B-cell lymphomas [1]. In 1993, the US Intergroup
study demonstrated that the standard of care in diffuse
large B-cell lymphoma (DLBCL) was cyclophosphamide,
adriamycin, vincristine, and prednisone (CHOP) admi-
nistered every 21 days (CHOP-21) for eight cycles [2].
Monoclonal antibody therapy in combination with
chemotherapy (immunochemotherapy) improved the
overall survival (OS) in DLBCL. Monoclonal antibody
therapy has subsequently been used in other aggressive
lymphomas as defined by the World Health Organiza-
tion (WHO) classification [3]. The most studied antigen
is a pan-B-cell antigen, CD20, which does not shed into
the cytoplasm, internalize, or undergo significant mod-
ulation. Other B-cell antibodies and T-cell antibodies
have entered the clinical arena. The WHO classification
of lymphomas has been further modified and in 2008
a new classification will define more than 50 types of
lymphoma [4]. Positron emission tomography (PET)
scans have altered the clinical staging of patients.
Recent advances
Classification and staging
The new fourth edition of the WHO lymphoma
classification further defines and differentiates non-
Hodgkin lymphoma (NHL) [4]. Follicular lymphoma
(FL) is defined as low-grade FL 1-2, intermediate-grade
FL 3A, and high-grade FL 3B, and there is no follicular
grade 3 lymphoma with DLBCL. DLBCL categories now
include T-cell-rich/histiocytic-rich large B-cell lym-
phoma, primary central nervous system, cutaneous
B-cell, Epstein Barr virus (EBV)-associated, lymphoma-
toid granulomatosis, and other categories. Other aggres-
sive lymphomas include B-cell lymphoma unclassified
intermediate between Burkitt lymphoma and DLBCL,
B-cell lymphoma intermediate between DLBCL and
classical Hodgkin lymphoma, EBV-associated T-cell
clonal lymphoproliferative disease, and anaplastic
large-cell lymphoma, alk-1-negative, provisional cate-
gory. These changes are the result of a vast and rapid
accumulation of biology and clinicopathologic observa-
tions that are beyond the scope of this review.
Functional imaging with 18-fluoro-deoxyglucose PET
(FDG-PET) has improved the accuracy of restaging
evaluationsafterprimarytreatmentforNHL.PETscanning
after one to four cycles of chemotherapy is a sensitive
indicator of tumor response and clinical outcome [5,6].
FDG-PET interpretations have been incorporated into
clinical trial response criteria and treatment guidelines
[7,8]. Response criteria for interim analysis are not the
same as those validated for the end of treatment analysis,
and PET is recommended 3 weeks after chemotherapy [7].
Positive PET scan lesions should be rebiopsied [9].
Treatment
Diffuse large B-cell lymphoma
Rituximab is a chimeric anti-CD20 human immuno-
globulin G1 monoclonal antibody approved for the
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improved progression-free survival (PFS) and OS,
which led to US Food and Drug Administration approval
for patients with new DLBCL in 2006. In the landmark
randomized prospective trial of R-CHOP versus CHOP
in elderly patients primarily with DLBCL, the Groupe
d’Etude des Lymphomes de l’Adulte (GELA) reported
superior PFS and OS with R-CHOP with rituximab
administered as rituximab on day one of each of eight
CHOP cycles compared with CHOP [9,10]. Three
hundred and ninety-nine patients 60 to 80 years old
were randomly assigned to receive eight cycles of CHOP
or R-CHOP (rituximab and CHOP). The 7-year PFS rates
were 52% for R-CHOP and 29% for CHOP (P <0.0001),
the DFS rates were 66% for R-CHOP and 42% for CHOP
(P = 0.0001), and the OS rates were 53% for R-CHOP
and 36% for CHOP (P = 0.0004) [10]. In the US
Intergroup Eastern Cooperative Oncology Group 4494/
Cancer and Leukemia Group B (CALGB) 9793 trial with
a median follow-up of 3.5 years, the estimated 2-year
failure-free survival (FFS) rates after second random
assignment were 77% for R-CHOP followed by observa-
tion, 79% for R-CHOP + maintenance rituximab (MR),
74% CHOP + MR, and 45% for CHOP followed by
observation (P <0.001) [11]. A secondary analysis was
performed to elucidate the effects of induction treatment
without MR. In this analysis, R-CHOP alone significantly
decreased the risk of treatment failure compared with
CHOP alone [hazard ratio (HR) = 0.64, 95% confidence
interval (CI), 0.47 to 0.85; P = 0.003] with estimated
3-year FFS rates of 52% for R-CHOP and 39% for CHOP.
In addition, OS was longer after R-CHOP induction
alone (HR = 0.72, 95% CI 0.52 to 1.00; P = 0.05) with
estimated 3-year OS rates of 67% for R-CHOP and 58%
for CHOP. The 3-year FFS (R-CHOP 53% and 52% and
CHOP 35% and 35%, respectively), OS (R-CHOP 62%
and 67% and CHOP 51% and 58%, respectively), and
respective FFS HR (0.58 and 0.64) and OS HR (0.72 and
0.72) were similar in the GELA and US Intergroup trials
despite differences in high-risk International Prognostic
Index (IPI) characteristics (R-CHOP 12% versus 23%
and CHOP 15% versus 27%, respectively). The contin-
ued use of MR after R-CHOP failed to demonstrate
a benefit at the time of the initial report or in follow-up
at 5.5 years [12]. At 7 years, 48% of the deaths were
secondary to lymphoma [13]. A Canadian population
study confirmed the OS observations of R-CHOP over
CHOP from the GELA and the US Intergroup trials [14].
The Mabthera International Trial (MinT) was a rando-
mized international trial of 824 young patients from 18
countries and 172 participating institutions of six cycles
of CHOP-like chemotherapy plus rituximab (413
patients, 355 evaluable for response) versus CHOP-like
therapy (411 patients, 350 evaluable for response) alone
in young patients with good-prognosis (favorable and
intermediate-risk) DLBCL with additional radiation
therapy to bulky and extranodal disease [15]. Patients
had zero or one adverse IPI factor. At a median follow-up
of 34 months (range of 0.03 to 61), patients treated with
chemotherapy and rituximab had an increased 3-year OS
of 93% (90 to 95%) versus 84% (80 to 88%) with a
difference between the groups of 9% (3 to 13%;
P = 0.0001). The efficacy was confirmed in a retrospective
population-based study [14].
Two studies demonstrated that standard-dose CHOP
administered every 14 days (CHOP-14) results in a
longer OS than CHOP-21 in patients 18 to 60 years old
or 61 to 75 years old [16,17]. Phase II studies evaluating
R-CHOP-14 have been reported [18–20]. An interna-
tional ongoing study of R-CHOP-21 versus R-CHOP-14
will further address the question of every-2-week versus
every-3-week R-CHOP by the French GELA and British
National Cancer Research Institute.
Future trials are evaluating other approaches. Epratuzu-
mab has been combined with R-CHOP-21 in the
treatment of previously untreated DLBCL [21]. Epratu-
zumab is a humanized monoclonal immunoglobulin
G1 antibody directed against the B-cell-specific antigen
CD22 that is expressed by pre-B cells and mature normal
B cells and is expressed in approximately 85% of DLBCL.
In the initial feasibility study of 15 patients with DLBCL,
the complete response (CR) rate was 67% and the partial
response (PR) rate was 20%. The 2-year PFS and OS rates
were 86% and 86%, respectively. The North Central
Cancer Treatment Group reported an expanded phase II
study of this regimen [22]. The infusion regimen DA-
EPOCH-R (dose-adjusted etoposide, prednisone, vincris-
tine, cyclophosphamide, doxorubicin, and rituximab)
has been developed at the National Cancer Institute
(Bethesda, MD, USA) and preliminary data demonstrate
that this regimen is effective among all biomarker
subgroups [23]. The CALGB has initiated a phase III
randomized study of R-CHOP-21 versus DA-EPOCH-R,
incorporating molecular profiling and pharmacoge-
nomics to determine whether DA-EPOCH-R represents
a treatment advance. The US Intergroup study (S9704) is
assessing the role of HDT and autologous transplanta-
tion after five cycles of R-CHOP versus completing eight
total cycles of R-CHOP-21 and no transplant in younger
patients with high-intermediate or high-risk disease.
New approaches to patients who have relapsed/refrac-
tory disease include the small molecules. Lenalidomide
(Revlimid
“) is an immunomodulatory drug that is being
evaluated at the phase II level. In 21 patients with
relapsed/refractory DLBCL, there were three CRs and two
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mTOR (mammalian target of rapamycin) is a key kinase
that regulates cell cycle progression from G1 to S phase.
In an initial phase II study, there were one CR and five
PRs with a 50% overall response rate (ORR) in patients
with aggressive lymphoma after a median of seven cycles
of treatment [25].
The standard of care after relapse after DLBCL is salvage
therapy followed by high-dose chemotherapy with stem
cell transplant [26]. In phase II trials, the addition of
rituximab to salvage chemotherapy regimens may
improve the ORR with ICE (ifosfamide, carboplatin,
and etoposide), EPOCH, and DHAP (dexamethasone,
cisplatin, and cytarabine) [27,28]. The Collaborative
Trial in Relapsed Aggressive Lymphoma (CORAL) and
other trials are addressing the questions of the most
optimal salvage regimens prior to stem cell transplant.
Primary mediastinal large B-cell lymphoma
Primary mediastinal large B-cell lymphoma is a subset of
DLBCL with distinct clinical characteristics that include a
mediastinal presentation in young females, unique
pathologic features that include sclerosis, and a unique
molecular gene expression signature with a more
favorable outcome than DLBCL. The 5-year OS in
patients less than 65 years old treated with CHOP-R
was 81% and the impact of rituximab was not
determined [29]. In a non-randomized series of patients,
26 patients were treated with DA-EPOCH and 26
patients were treated with DA-EPOCH-R [30]. Rituximab
was associated with a significantly improved event-free
survival (P = 0.038) and OS (P = 0.023).
Burkitt lymphoma
Burkitt lymphoma is a rare lymphoma. Dose-adjusted
(DA) chemotherapy that is adjusted by pharmacoky-
namics, DA-EPOCH-R, was administered over the course
of 4 days for six cycles in 13 HIV-negative patients and
three to six cycles in six HIV-positive patients and
resulted in a CR rate of 100% in 19 patients [31]. At a
median follow-up of 28 months, all patients were alive
and in remission.
Post-transplant lymphoprolilferative disorders
The most common post-transplant lymphoproliferative
disorder (PTLD) is the monomorphic DLBCL, which is
highly associated with immunosuppressive treatment
and EBV. In a phase II study of rituximab, the ORR was
44% with a CR rate of 35% with few relapses and 65% of
patients had delayed-onset PTLD, which likely accounted
for the lower response rate [32].
Follicular lymphoma
Before the immunochemotherapy era in follicular
lymphoma, therapeutic approaches improved the dura-
tion of response and only marginally improved OS.
There are now four trials that have reported an improved
OS with the addition of rituximab to CVP (cyclopho-
sphamide, vincristine, and prednisone), CHOP, MCP
(mitoxantrone, chlorambucil, and prednisolone), and
CHVP+I (CHOP + interferon) [33–37]. Radioimmuno-
conjugate therapy with
131I-tositumomab in patients
with limited bone marrow involvement produced a 59%
5-year PFS in the first-line treatment of patients with
FL [38].
Other studies
Ongoing studies are evaluating surrogate markers for the
cell of origin microarray signature [39]. However, at this
time, 20 to 40% of patients are not defined by standard
immunohistochemical markers [39]. Host germ-line
immune gene single-nucleotide polymorphisms are
predictive of survival in FL and DLBCL [40,41]. Future
strategies will define biologically defined prognostic
factors in FL that are not available at this time.
Implications for clinical practice
The new WHO classification will be incorporated into
clinical trials. This will necessitate incorporation of this
classification into routine pathology and clinical prac-
tice. PET scans now predict outcome and are incorpo-
rated into clinical trials in DLBCL and other lymphomas
to evaluate the most optimal timing of a repeat PET scan
following the initiation of treatment. The utility of PET
scans in follicular and low-grade lymphoma is under
further evaluation. Rituximab has now improved the OS
in DLBCL and FL for the first time in over 25 years.
Ongoing studies are further refining the incorporation of
rituximab into treatment regimens. By December 2007,
there were over 17 international randomized phase III
studies in DLBCL [42]. Critical ongoing trials in FL
include the US Intergroup trial comparing R-CHOP
versus CHOP followed by tositumomab, and the GELA
PRIMA (Primary Rituximab and Maintenance) study
evaluating the role of 2 years of MR therapy after a
rituximab chemotherapy induction regimen will further
define the new treatment paradigms. New oral agents are
demonstrating significant activity in B-cell lymphomas
with different mechanisms of action. These provide
patients with new opportunities for therapeutic inter-
ventions following relapse. New observations in the
biology of the disease will change treatment approaches.
In conclusion, targeted therapies with monoclonal anti-
bodies and monoclonal antibodies conjugated to radio-
immunoconjugates have altered the natural history of
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membraneandcellularpathwayswillcontinuetoalterthe
natural history of the multiple histologies of B-cell NHL.
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